Access sought to tuberculosis drug from nutraceutical company

Canadian approval sought for controversial pain drug.

FDA to review "missing" drug company documents.

Delamanid expanded access novel treatment of drug resistant tuberculosis

Tuberculosis (TB) remains a global emergency and is one of the most common infectious disease causes of death in developing countries. Current treatment regimens for multi-drug resistant TB are associated with low treatment success rates, are toxic, and require long duration of treatment. The need for shorter and more effective treatment regimens is urgent. Delamanid (Deltyba, or formerly known...

A STUDY OF MYCOBACTERIUM TUBERCULOSIS DRUG RESISTANCE IN PULMONARY TUBERCULOSIS

Tuberculosis remains a major public health problem in both developing and developed countries. Drug-resistant tuberculosis is an increasing health problem and serious challenge to tuberculosis (TB) control programs. Information about the susceptibility pattern of Mycobacterium tuberculosis isolates against anti-tuberculosis drugs is an important aspect to TB control. The objectives of the s...

HPV vaccines: separating real hope from drug company hype.

in 2008, Harald Zur Hausen received the nobel Prize in physiology and medicine for showing that two human papilloma viruses, HPV16 and HPV18, were associated with the bulk of cervical cancers, and that some of the genes contained within the viruses were incorporated into the infected host tissue, resulting in carcinogenesis. These carcinogenic strains of HPV cause 70% of cervical cancer and kil...